[go: up one dir, main page]

MX2010002003A - Metodo de produccion. - Google Patents

Metodo de produccion.

Info

Publication number
MX2010002003A
MX2010002003A MX2010002003A MX2010002003A MX2010002003A MX 2010002003 A MX2010002003 A MX 2010002003A MX 2010002003 A MX2010002003 A MX 2010002003A MX 2010002003 A MX2010002003 A MX 2010002003A MX 2010002003 A MX2010002003 A MX 2010002003A
Authority
MX
Mexico
Prior art keywords
methods
amplification
selection
cell lines
frames
Prior art date
Application number
MX2010002003A
Other languages
English (en)
Inventor
Mark Uden
Ekaterini Kotsopoulou
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2010002003A publication Critical patent/MX2010002003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para reducir los niveles de presión elegibles titulables requeridos, la cantidad de ciclos de amplificación, y el tiempo que tarda generar las líneas celulares de expresión de proteína alterando los codones de las fases de lectura abiertas deseadas. A través del uso de la adaptación al codón para este propósito, los métodos de la invención proporcionan constantemente suficientes producciones en períodos de tiempo más rápidos que ahorran muchas semanas de actividades de desarrollo de línea celular. Además los métodos de la invención también generan líneas celulares con concentraciones más bajas de agente de selección y amplificación que las que se pudieron alcanzar previamente. Por consiguiente, se observan niveles inferiores de marcador de selección y amplificación en las líneas celulares finales.
MX2010002003A 2007-08-20 2008-08-19 Metodo de produccion. MX2010002003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95677207P 2007-08-20 2007-08-20
PCT/EP2008/060834 WO2009024567A1 (en) 2007-08-20 2008-08-19 Production method

Publications (1)

Publication Number Publication Date
MX2010002003A true MX2010002003A (es) 2010-03-10

Family

ID=40070558

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002003A MX2010002003A (es) 2007-08-20 2008-08-19 Metodo de produccion.

Country Status (13)

Country Link
US (2) US9163249B2 (es)
EP (3) EP2185591B1 (es)
JP (2) JP5592258B2 (es)
KR (1) KR101637533B1 (es)
CN (1) CN101848936B (es)
AU (1) AU2008290607B2 (es)
BR (1) BRPI0815576A2 (es)
CA (1) CA2695484C (es)
DK (1) DK3216802T3 (es)
EA (1) EA022990B1 (es)
ES (2) ES2840725T3 (es)
MX (1) MX2010002003A (es)
WO (1) WO2009024567A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3216802T3 (da) * 2007-08-20 2021-01-04 Glaxo Group Ltd Produktionsfremgangsmåde
MX346700B (es) * 2009-03-10 2017-03-28 Dsm Ip Assets Bv Metodo para mejorar el rendimiento de un polipeptido.
AU2010340358B2 (en) * 2009-12-21 2014-07-24 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
JP6039552B2 (ja) 2010-07-01 2016-12-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 高産生細胞株を選択するための改良された方法
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
KR20150110659A (ko) 2013-01-24 2015-10-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tnf-알파 항원-결합 단백질
MX2018005084A (es) * 2015-11-05 2019-05-16 Bamboo Therapeutics Inc Genes de ataxia de friedreich modificados y vectores para terapia genica.
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
JP7389741B2 (ja) 2017-09-13 2023-11-30 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー Ｔ細胞受容体または人工ｔ細胞受容体を発現するためのｒｎａレプリコン
CN111094549B (zh) 2017-09-13 2024-11-01 生物技术公司 用于将体细胞重编程的rna复制子
CN116615551A (zh) 2020-06-04 2023-08-18 生物技术公司 用于多用途和有效的基因表达的rna复制子
WO2023066875A1 (en) 2021-10-18 2023-04-27 BioNTech SE Modified replicable rna and related compositions and their use
WO2023066874A1 (en) 2021-10-18 2023-04-27 BioNTech SE Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
WO2023213378A1 (en) 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
JP2025532591A (ja) 2022-09-15 2025-10-01 ビオンテック・ソシエタス・エウロパエア ｍｉＲＮＡを有するトランス増幅ＲＮＡベクターを含むシステムおよび組成物
WO2024165146A1 (en) 2023-02-07 2024-08-15 Biontech Cell & Gene Therapies Gmbh Immune effector cells stably and transiently expressing nucleic acids
KR20250169566A (ko) 2023-04-14 2025-12-03 바이오엔테크 에스이 Hiv 백신
WO2025040709A1 (en) 2023-08-24 2025-02-27 BioNTech SE Systems and compositions comprising highly active trans-amplifying replicases
WO2025051381A1 (en) 2023-09-08 2025-03-13 BioNTech SE Methods and compositions for localized expression of administered rna

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
JP2005509403A (ja) * 2001-03-27 2005-04-14 スミスクライン・ビーチャム・コーポレイション ＩｇＧにおけるグリコフォームの制御
WO2004032868A2 (en) * 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
AU2003294297A1 (en) * 2002-11-15 2004-06-15 The Henry M. Jackson Foundation Recombinant hiv-1 subclass d envelope glycoproteins
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
WO2005111623A1 (en) * 2004-05-17 2005-11-24 Crucell Holland B.V. Methods for diagnosis of acute myeloid leukemia
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US8916165B2 (en) * 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
AU2006208226A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
CA2606576A1 (en) * 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
WO2007068429A1 (en) * 2005-12-12 2007-06-21 F. Hoffmann-La Roche Ag Antibodies against amyloid beta 4 with glycosylated in the variable region
US8227576B2 (en) 2006-03-30 2012-07-24 Glaxo Group Limited Antibodies against amyloid-β peptide
TW200815470A (en) * 2006-03-30 2008-04-01 Novartis Ag Compositions and methods of use for antibodies of c-Met
DK3216802T3 (da) * 2007-08-20 2021-01-04 Glaxo Group Ltd Produktionsfremgangsmåde

Also Published As

Publication number Publication date
CN101848936A (zh) 2010-09-29
ES2840725T3 (es) 2021-07-07
WO2009024567A1 (en) 2009-02-26
EP2527367A1 (en) 2012-11-28
JP2015027298A (ja) 2015-02-12
EP3216802A1 (en) 2017-09-13
EP2185591A1 (en) 2010-05-19
JP6029625B2 (ja) 2016-11-24
US9163249B2 (en) 2015-10-20
CA2695484A1 (en) 2009-02-26
EP2185591B1 (en) 2014-05-14
KR101637533B1 (ko) 2016-07-11
EP3216802B1 (en) 2020-10-07
BRPI0815576A2 (pt) 2015-02-18
US20110040074A1 (en) 2011-02-17
AU2008290607A1 (en) 2009-02-26
CA2695484C (en) 2018-05-01
DK3216802T3 (da) 2021-01-04
ES2473623T3 (es) 2014-07-07
EA201000205A1 (ru) 2011-02-28
EA022990B1 (ru) 2016-04-29
JP5592258B2 (ja) 2014-09-17
KR20100065332A (ko) 2010-06-16
US20160010111A1 (en) 2016-01-14
US10633673B2 (en) 2020-04-28
CN101848936B (zh) 2017-05-03
AU2008290607B2 (en) 2013-11-14
JP2010536358A (ja) 2010-12-02

Similar Documents

Publication Publication Date Title
MX2010002003A (es) Metodo de produccion.
WO2011090726A3 (en) Use of a natural metabolite to increase crop production
WO2011130402A3 (en) Hepatocyte production by forward programming
SG196784A1 (en) Stem cell cultures
MY159971A (en) Multipotent/pluripotent cells and methods
MX342569B (es) Dispositivo de doble poro.
WO2011071476A3 (en) Compositions and methods for engineering cells
MX2014014337A (es) Metodo de produccion de alta concentracion de celulas madre.
WO2009149956A3 (en) Fusion protein and use thereof
IN2012DN02333A (es)
WO2010128024A3 (en) Reversibly immortalized cells as well as methods relating hereto
WO2010078952A3 (de) Strukturierte gasdiffusionselektrode für elektrolysezellen
MX338752B (es) Metabolismo microbiano de oxianiones cloro como control de produccion de sulfuro de hidrogeno biogenico.
IN2013CN00342A (es)
MY155330A (en) Methods for salt production
MX354183B (es) Metodo de operacion de la fermentacion de un substrato gaseoso que comprende hidrogeno.
IN2012DN00852A (es)
WO2008060792A3 (en) Novel cells, compositions, and methods
WO2009137146A3 (en) Method for producing continuous cell lines
WO2013012889A3 (en) Regulatory polynucleotides and uses thereof
WO2011004968A3 (ko) 조직 재생용 구조체 및 그 제조방법
AU2012262554A8 (en) Extracellular matrix material conduits and methods of making and using same
PH12013501043B1 (en) Plasmodiophora brassicae-resistant brassica plant, seeds and plant parts thereof and methods for obtaining the same
WO2009004664A8 (en) Immortalized cell line of murine mesenchymal stem cells, method for preparation and uses thereof
GB2495059A (en) Mammalian model for amplification of cancer stem cells

Legal Events

Date Code Title Description
FA Abandonment or withdrawal